LUND, Sweden, Sept. 2, 2020 /PRNewswire/ -- Immunovia AB (publ)
("Immunovia") a near-commercial stage diagnostics company
developing ground-breaking antibody-based multiplex microarray
technology platform called IMMray™ for the early detection of
cancer, announced today that Dr. Peter
Schultz-Knappe, Chief Technology Officer, is stepping down
from his position to pursue other opportunities effective on
August 31, 2020. Hans Christian Pedersen, Vice-President of
Business Development, will assume Peter's duties and become
Immunovia's Vice President of Strategy and Business
Development.
Hans Christian's expanded
responsibilities will include business development, pipeline
portfolio strategy, and technology strategy. He has 16+ years of
industry experience working with companion diagnostics development,
marketing and scientific affairs. Prior to his time with Unilabs,
he was the Director of Scientific Affairs, Global Marketing at
Agilent Technologies.
"We appreciate the many contributions Peter made since joining
the Immunovia team as CTO. We would like to thank Peter for his
time at Immunovia," stated Mats
Grahn, CEO of Immunovia. "Our senior leadership team is
pleased to continue the work together with Hans Christian in this new capacity as we
continue ramping up commercialization towards IMMray™ PanCan-d's Q4
2020 launch."
For more information, please contact:
Julie Silber
Director of Investor Relations
Email: julie.silber@immunovia.com
Tel: +46 7 93 486 277
This is information that Immunovia is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact person
set out above, at 8:30 CET on
September 2, 2020.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently in the final validation for sales start Q4 2020.
When validated, IMMray™ PanCan-d will be the first blood-based test
for early diagnosis of pancreatic cancer on the market, with a
potential to significantly improve patient survival and
outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-announces-management-team-changes,c3187130
The following files are available for download:
https://mb.cision.com/Main/13121/3187130/1301063.pdf
|
Release
|